Kyntra Bio Inc
KYNB Healthcare Biotechnology
In the quarter to June 2026, revenue fell 209.4%, EPS grew 257.5% and free cash flow fell 131.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KYNB
Kyntra Bio Inc (KYNB) EV/Sales
As of 16 October 2026, Kyntra Bio Inc (KYNB) trades at a EV/Sales of 16.3×. Over the past ten years it has ranged from −9.5× (July 2024) to 35.8× (June 2018); the current reading is higher than 74% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.5× | 392.28% |
| FY2024 | 3.0× | — |
| FY2023 | −0.8× | — |
| FY2022 | 8.4× | 94.12% |
| FY2021 | 4.3× | (71.69%) |
| FY2020 | 15.2× | 20.86% |
| FY2019 | 12.6× | (20.29%) |
| FY2018 | 15.8× | (32.39%) |
| FY2017 | 23.4× | 262.75% |
| FY2016 | 6.4× | (33.57%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 18.7× | 59.36% |
| Mar 2026 | 11.7× | (19.27%) |
| Dec 2025 | 14.5× | 53.35% |
| Sep 2025 | 9.5× | (52.02%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.3× |
| COCP Cocrystal Pharma, Inc. compare | 8.9× |
| KYNB Kyntra Bio Inc | 16.3× |
| QNTM Quantum Biopharma Ltd. compare | 28.8× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)